---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-086059"
form_type: "8-K"
ticker: null
cik: "0001305253"
company_name: "Eiger BioPharmaceuticals, Inc."
filed_at: "2024-04-03T23:59:59+00:00"
generated_at: "2026-06-04T02:45:34.848352+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Eiger BioPharmaceuticals files Chapter 11, receives Nasdaq delisting notice; shares to trade OTC

## Summary
- Filed Chapter 11 petitions on April 1, 2024; Nasdaq issued delisting notice on April 2.
- Company will not appeal; trading suspended on Nasdaq effective April 11, 2024.
- Common stock expected to trade OTC under symbol EIGRQ starting April 11, 2024.
- Director Jeffrey S. Glenn resigned April 1, 2024, citing no disagreement with the company.

## SEC filing metadata
- accession: 0001193125-24-086059
- form_type: 8-K
- cik: 0001305253
- company_name: Eiger BioPharmaceuticals, Inc.
- filed_at: 2024-04-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 3.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1305253/000119312524086059/0001193125-24-086059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1305253/000119312524086059/d819347d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-086059
- JSON: https://secwatch.observer/filing/0001193125-24-086059.json
- Plain text: https://secwatch.observer/filing/0001193125-24-086059.txt

## Key facts
- Listing & Compliance Notices
  Eiger BioPharmaceuticals, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Rules: 5101, 5110(b), IM-5101-1
  source text: April 2, 2024, the Company received written notice (the “ Delisting Notice ”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, as a result of the Bankruptcy Petitions and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, Nasdaq had determined that the Company’s common stock will be delisted from Nasdaq. The Delisting Notice also advises the Company of its right to appeal Nasdaq’s determination pursuant to procedures set forth in Nasdaq Listing Rule 5800 Series. The Company does not intend to pursue an appeal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1305253/000119312524086059/0001193125-24-086059-index.htm
- Executive change
  Jeffrey S. Glenn resigned as Member of the Board of Directors at Eiger BioPharmaceuticals, Inc..
  - Action: resigned
  - Role: Member of the Board of Directors
  source text: On April 1, 2024, Jeffrey S. Glenn notified the Company of his resignation as a member of the Company’s Board of Directors, to be effective April 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1305253/000119312524086059/0001193125-24-086059-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.